Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb;34(1):93-9.
doi: 10.1007/s10545-010-9151-1. Epub 2010 Jun 22.

The homocysteine controversy

Yvo M Smulders  1 , Henk J Blom
Affiliations
Review

The homocysteine controversy

Yvo M Smulders et al. J Inherit Metab Dis. 2011 Feb.

Abstract

Mild to moderate hyperhomocysteinemia has been identified as a strong predictor of cardiovascular disease, independent from classical atherothrombotic risk factors. In the last decade, a number of large intervention trials using B vitamins have been performed and have shown no benefit of homocysteine-lowering therapy in high-risk patients. In addition, Mendelian randomization studies failed to convincingly demonstrate that a genetic polymorphism commonly associated with higher homocysteine levels (methylenetetrahydrofolate reductase 677 C>T) is a risk factor for cardiovascular disease. Together, these findings have cast doubt on the role of homocysteine in cardiovascular disease pathogenesis, and the homocysteine hypothesis has turned into a homocysteine controversy. In this review, we attempt to find solutions to this controversy. First, we explain that the Mendelian randomization analyses have limitations that preclude final conclusions. Second, several characteristics of intervention trials limit interpretation and generalizability of their results. Finally, the possibility that homocysteine lowering is in itself beneficial but is offset by adverse side effects of B vitamins on atherosclerosis deserves serious attention. As we explain, such side effects may relate to direct adverse effects of the B-vitamin regimen (in particular, the use of high-dose folic acid) or to proinflammatory and proproliferative effects of B vitamins on advanced atherosclerotic lesions.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Principle of Mendelian randomization as applied to hyperhomocysteinemia. This is the ideal model of Mendelian randomization. Essential for the validity of the model is the absence of arrows between the gene and (known or unknown) confounders, as well as the absence of an arrow (i.e., a direct association not dependent on the risk factor) between the gene and the disease. MTHFR methylenetetrahydrofolate reductase, CVD cardiovascular disease
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022 - PubMed
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653 - PMC - PubMed
    1. Antohe F, Radulescu L, Puchianu E, Kennedy MD, Low PS, Simionescu M. Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia. Cell Tissue Res. 2005;320:277–285. doi: 10.1007/s00441-004-1071-7. - DOI - PubMed
    1. Carnicer R, Navarro A, Arbonqs-Mainar JM, AcÆn S, Guzmbn MA, Surra JC, et al. Folic acid supplementation delays atherosclerotic lesion development in apoE-deficient mice. Life Sci. 2007;80:638–643. doi: 10.1016/j.lfs.2006.10.014. - DOI - PubMed
    1. Clarke R (2009) Evidence against a causal association of homocysteine and coronary heart disease: a mendelian randomisation study. Data presented at the 7th international conference on homocysteine metabolism, Prague, Chech Republik

MeSH terms